Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06795529 · ClinicalTrials.gov registry record · NA
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
A NA study of Metastatic Breast Cancer, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 3
- Study locations
NCT06795529 is a NA study of Metastatic Breast Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 400 participants, above the 202-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (98% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT06795529, a NA study of Metastatic Breast Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 3
- Study locations
Study Summary
Many people living with metastatic breast cancer face challenging symptoms and frequent medical visits. At the same time, conversations about personal goals, values, and preferences for care may not always happen as early or as often as patients and families would like. This multi-site study will test the effectiveness of a five-session palliative care program, designed specifically for people with metastatic breast cancer and their caregivers, to strengthen communication with clinicians about what matters most in their care. The study aims to inform how palliative care services can be delivered in a more timely, personalized, and scalable way for people living with advanced cancers who have long disease trajectories, such as metastatic breast cancer.
Conditions Studied
Interventions
- OTHER Enhanced Usual Care
- OTHER Palliative Care Intervention, "TARGET-PC"
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
North Carolina
- Duke University - Durham
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2030-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06795529
The ClinicalTrials.gov registry entry for NCT06795529 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 202-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (98% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enhanced Usual Care is the first listed.
NCT06795529 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06795529 about?
NCT06795529 is a clinical study titled "Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer". Many people living with metastatic breast cancer face challenging symptoms and frequent medical visits. At the same time, conversations about personal goals, values, and preferences for care may not always happen as early or as often as patients and families would like. This multi-site study will te...
What is the current status of trial NCT06795529?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2025-10-01. Estimated completion is 2030-03-31.
What conditions does trial NCT06795529 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT06795529?
The interventions under investigation include: Enhanced Usual Care (OTHER), Palliative Care Intervention, "TARGET-PC" (OTHER).
Who is sponsoring clinical trial NCT06795529?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06795529 being conducted?
This trial has 3 study locations across Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
RECRUITING · NA
-
Adaptation of a Values Assessment Tool
RECRUITING · NA
-
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
RECRUITING · NA
-
Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
RECRUITING · NA
-
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
RECRUITING · NA
-
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.